Changes

no edit summary
Line 148: Line 148:  
|
 
|
 
|-
 
|-
|Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms||'''''Overview'''''|| ||Example
+
|Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms||'''''Overview'''''|| ||Jennelle Hodge (JH)
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||'''''Overview'''''|| ||Example
+
|Myeloid Neoplasms with Germline Predisposition||'''''Overview'''''|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Acute Myeloid  Leukaemia with Germline CEBPA Mutation||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Myeloid Neoplasms  with Germline DDX41 Mutation||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Myeloid Neoplasms  with Germline RUNX1 Mutation||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Myeloid Neoplasms  with Germline ANKRD26 Mutation||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Myeloid Neoplasms  with Germline ETV6 Mutation||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Myeloid Neoplasms  with Germline GATA2 Mutation||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Acute Myeloid Leukemia (AML) with Recurrent Genetic  Abnormalities||'''''Overview'''''|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Acute Myeloid  Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Acute Myeloid  Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Acute Promyelocytic  Leukemia (APL) with PML-RARA||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Acute Myeloid  Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Acute Myeloid  Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Acute Myeloid  Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Acute Myeloid  Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Acute Myeloid  Leukemia (AML) with BCR-ABL1||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Acute Myeloid  Leukemia (AML) with Mutated NPM1||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Acute Myeloid  Leukemia (AML) with Biallelic Mutations of CEBPA||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Acute Myeloid  Leukemia (AML) with Mutated RUNX1||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Therapy-Related Myeloid Neoplasms||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Example|| || ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Example|| || ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Example|| || ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Example|| || ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Example|| || ||Example
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Example|| || ||Example
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Example|| || ||Example
 
|
 
|
 
|
 
|